Stockscreener 앱 받기
6.28
0.16%
-0.010
시간 외 거래:
6.28
Aura Biosciences Inc 주식(AURA)의 최신 뉴스
Aura Biosciences Holds 2025 Annual Stockholders Meeting - TipRanks
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Harbor Capital Advisors Inc. Takes Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
PTC Brings Cloud-Native Model-Based Definition to Onshape - The Globe and Mail
Company News for Jun 13, 2025 - The Globe and Mail
Bank of America Corp DE Increases Stock Holdings in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Two Sigma Investments LP Reduces Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail
Kernaghan buying at Western Forest Products (WEF) - The Globe and Mail
BNP Paribas Financial Markets Invests $50,000 in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
15,427 Shares in Aura Biosciences, Inc. (NASDAQ:AURA) Acquired by ProShare Advisors LLC - Defense World
Ameriprise Financial Inc. Has $704,000 Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Option Volatility And Earnings Report For June 26 - The Globe and Mail
Learn to Evaluate (AURA) using the Charts - news.stocktradersdaily.com
Brokers Set Expectations for AURA Q2 Earnings - Defense World
Deutsche Bank AG Buys 15,951 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of “Buy” from Analysts - Defense World
Equities Analysts Offer Predictions for AURA FY2028 Earnings - Defense World
Aura Biosciences (NASDAQ:AURA) Raised to Buy at HC Wainwright - Defense World
H.C. Wainwright sets $22 target for Aura Biosciences stock By Investing.com - Investing.com Canada
Aura Biosciences (AURA) Receives 'Buy' Rating from HC Wainwright & Co. | AURA Stock News - GuruFocus
H.C. Wainwright sets $22 target for Aura Biosciences stock - Investing.com
Aura Biosciences assumed with a Buy at H.C. Wainwright - TipRanks
AURA: Analyst Initiates Buy Rating with $22 Price Target | AURA Stock News - GuruFocus
Innovative Precision Oncology and Promising Clinical Results Justify Buy Rating for Aura Biosciences Inc - TipRanks
Aura Biosciences (NASDAQ:AURA) Earns Market Outperform Rating from JMP Securities - Defense World
Northern Trust Corp Has $3.18 Million Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
JMP maintains $19 target on Aura Biosciences stock after FDA insights - Investing.com Canada
AURA: JMP Securities Reiterates Market Outperform Rating | AURA Stock News - GuruFocus
Strategic Positioning and Regulatory Advantage Bolster Aura Biosciences Inc’s Buy Rating - TipRanks
Finance Watch: Public Company Fundraising Sank Across The Board In Q1 - insights.citeline.com
Anthony Gibney Buys 721% More Aura Biosciences Shares - simplywall.st
Long Term Trading Analysis for (AURA) - news.stocktradersdaily.com
Aura Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Major Stock Moves: Aura Biosciences Inc Sees Insider Buying Spree! - TipRanks
Promising Developments and Strategic Advancements Propel Aura Biosciences Inc’s Buy Rating - TipRanks
Aura Biosciences Advances in Cancer Therapy Trials - TipRanks
Aura Biosciences Raises $69.9 Million in Public Offering - TipRanks
Aura Biosciences announces public offering; shares down - MSN
Aura Biosciences: Strategic Advancements and Clinical Progress Drive Buy Rating - TipRanks
FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences Launches Public Offering Of Common Stock And Warrants - Nasdaq
Aura Biosciences announces common stock, warrant offering, no amount given - TipRanks
Aura Biosciences Prices $75 Million Offering of Shares, Warrants - marketscreener.com
Aura Biosciences sets terms for $75 million public offering By Investing.com - Investing.com India
Aura Biosciences sets terms for $75 million public offering - Investing.com Australia
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - GlobeNewswire
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - Benzinga
Aura Biosciences Secures $75M Funding: Major Push for Precision Cancer Treatment Development - Stock Titan
Aura Biosciences Launches Proposed Public Offering of Shares, Warrants - marketscreener.com
Aura Biosciences (AURA) Initiates Public Offering with Multiple Financial Managers | AURA Stock News - GuruFocus
Aura Biosciences Appoints New Chief Financial Officer - TipRanks
Aura Biosciences Announces Proposed Public Offering Of Common Stock And Warrants - marketscreener.com
Aura Biosciences, Inc. SEC 10-Q Report - TradingView
Aura Biosciences Enrolls First Patient in Phase 1b/2 Trial of Bel-sar for Non-Muscle-Invasive Bladder Cancer and Strengthens Leadership Team with New Appointment - Nasdaq
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants - GlobeNewswire
Major Cancer Therapy Developer Aura Biosciences Announces Strategic Public Offering with Top Wall Street Banks - Stock Titan
Aura Biosciences Hits Major Milestone in Bladder Cancer Trial, Reveals Strong Pipeline Progress - Stock Titan
Dimensional Fund Advisors LP Buys 73,062 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
(AURA) Trading Advice - news.stocktradersdaily.com
1.11%
1.70%
자본화:
|
볼륨(24시간):